There was an ORR of 40% (25.6–56.7) in NSCLC EGFR wild-type patients, and the most common grade 3 or higher treatment-related adverse events were leukopenia (30%), neutropenia (34%), and anemia (15%). This evidence concerns the gene EGFR and non-small cell lung carcinoma.